Accessibility Menu
NeuroScientific Biopharmaceuticals logo

NeuroScientific Biopharmaceuticals(ASX) NSB

Market CapA$24.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-72%
5 Year-83%
1 Year-64%
1 Month+5%
A$0.06
-1.59%
-0.00Today
NeuroScientific Biopharmaceuticals last closing stock price
MetricPriceDate
Last closeAUD 0.062026-09-08
NeuroScientific Biopharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.13%AUD 0.062026-09-01
1 month+5.08%AUD 0.062026-08-07
3 month-1.59%AUD 0.062026-06-10
Year to date-43.64%AUD 0.112025-12-31
1 year-63.53%AUD 0.172025-09-08
3 year-30.34%AUD 0.092023-09-07
5 year-83.24%AUD 0.372021-09-09
Since inception-72%AUD 0.232018-07-27

NeuroScientific Biopharmaceuticals Financials at a Glance

Market Cap

A$24.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$0.00

Net Income (TTM)

-A$6.54M

EPS (TTM)

-A$0.01

P/E Ratio

-4.46

Dividend

A$0.00

Beta (Volatility)

-0.17 (Low)

Price

A$0.06

Volume

11,523

Open

A$0.06

Previous Close

A$0.06

Daily Range

A$0.06 - A$0.06

52-Week Range

A$0.06 - A$0.18

Estimated Earnings Date

Feb 24, 2026

NSB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NeuroScientific Biopharmaceuticals

NeuroScientific Biopharmaceuticals Limited is an innovative biotechnology company focused on developing medical therapies for neurodegenerative conditions. Established in 2002 and headquartered in Cottesloe, Australia, the company utilizes proprietary technological platforms to advance its primary pharmaceutical compound, EmtinB, targeting diseases such as Alzheimer's and other degenerative disorders.

Products and Services
  • Development of EmtinB for neurodegenerative diseases
  • Extensive preclinical and clinical research capabilities
  • Proprietary technological platforms for drug development
Growth Outlook
  • Strong focus on neurodegenerative conditions with increasing global prevalence
  • Potential for EmtinB to address significant unmet medical needs
  • Strategic partnerships may enhance research and development capabilities
Financial Highlights
  • Recent quarterly revenue of 0, indicating ongoing investment in R&D
  • Cash and short-term investments of AUD 6.36 million as of December 2025
  • Current ratio of 31.62, reflecting strong liquidity position
NeuroScientific Biopharmaceuticals Limited is positioned in a growing sector with a focus on addressing critical health challenges. The company's commitment to research and development, particularly with EmtinB, highlights its potential to make significant contributions to the treatment of neurodegenerative diseases. The financial position, characterized by substantial liquidity, supports ongoing research efforts and positions the company for future growth. Investors may find the company's innovative approach and strategic focus appealing as it navigates the complexities of the biotechnology landscape.
AI Generated • Aug 17, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Nathan Smith

Website

www.neuroscientific.com

Headquarters

Perth, WA 6000, AU

NSB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-30.02%

Return on Capital

-34.29%

Return on Assets

-30.91%

Earnings Yield

-22.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$24.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

389.72M

Volume

11.52K

Avg. Volume

259.70K

Financials (TTM)

Gross Profit

-A$1.48M

Operating Income

-A$7.08M

EBITDA

-A$5.64M

Operating Cash Flow

-A$232.06K

Capital Expenditure

A$0.00

Free Cash Flow

-A$232.06K

Cash & ST Invst.

A$4.63M

Total Debt

A$87.04K

NeuroScientific Biopharmaceuticals Performance Analysis

NeuroScientific Biopharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
NeuroScientific Biopharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-100.0%
Q42025-06-30N/A
Q22025-12-31N/A
Q42026-06-30N/A
NeuroScientific Biopharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-89.8%
20242024-06-30AUD 0.00N/A
20252025-06-30AUD -0.01N/A
20262026-06-30AUD -0.0110.3%
NeuroScientific Biopharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-123.4%
Q42025-06-30-304.0%
Q22025-12-3149.5%
Q42026-06-30-72.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$761.46K

-1457.0%

Gross Margin

0.00%

N/A

Market Cap

A$24.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.68M

N/A

Employees

9

N/A

Net Income

-A$2.99M

-292.6%

EBITDA

-A$2.21M

-237.9%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$4.63M

-6.5%

Total Debt

A$87.04K

N/A

Accounts Receivable

A$128.41K

+135.7%

Inventory

A$0.00

N/A

Long Term Debt

A$38.73K

N/A

Short Term Debt

A$48.31K

N/A

Return on Assets

-30.91%

N/A

Return on Invested Capital

-34.40%

N/A

Free Cash Flow

-A$908.40K

+42.3%

Operating Cash Flow

-A$908.40K

+42.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PIQ.AXProteomics International Laboratories Ltd.
A$0.15-3.33%
NOX.AXNoxopharm Limited
A$0.07-1.41%
RAD.AXRadiopharm Theranostics Limited
A$0.01-10.00%
NXS.AXNext Science Limited
A$0.15+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$105.53+0.10%
NOKNokia
$10.80+0.08%
NVDANvidia
$226.29-0.02%
BNCCea Industries
$5.26+0.51%

Questions About NSB

What is the current price of NeuroScientific Biopharmaceuticals?

NeuroScientific Biopharmaceuticals is trading at A$0.06 per share.

What is the 52-week range for NeuroScientific Biopharmaceuticals?

Over the past 52 weeks, NeuroScientific Biopharmaceuticals has traded between A$0.06 and A$0.18.

How much debt does NeuroScientific Biopharmaceuticals have?

As of the most recent reporting period, NeuroScientific Biopharmaceuticals reported total debt of A$87.04K.

How much cash does NeuroScientific Biopharmaceuticals have on hand?

NeuroScientific Biopharmaceuticals reported A$2.63M in cash and cash equivalents in its most recent financial results.

What is NeuroScientific Biopharmaceuticals’s dividend yield?

NeuroScientific Biopharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services